Table 2.
Patient treatment characteristics
| N | % | |
|---|---|---|
| Total dose (Gy (RBE)) |
|
|
| 50.6–60 |
7 |
43 |
| 61.6–70 |
11 |
21 |
| 70.4–80 |
10 |
11 |
| Dose/fraction (Gy (RBE)) |
|
|
| 2.0 |
2 |
7 |
| 2.2 |
20 |
71 |
| 2.4 |
5 |
18 |
| 3.2 |
1 |
4 |
| BED10 (α/β = 10) (Gy) |
|
|
| 61.7–69.5 |
6 |
21 |
| 72.5–75.1 |
10 |
36 |
| 83.2–89.3 |
10 |
36 |
| 91.3–105.6 |
2 |
7 |
| BED3 (α/β = 3) (Gy) |
|
|
| 87.7–98.8 |
6 |
21 |
| 103.0–108.0 |
10 |
36 |
| 116.7–118.2 |
3 |
11 |
| 122.2–165.3 |
9 |
32 |
| History of chemotherapy |
|
|
| None |
18 |
64 |
| Completed |
10 |
36 |
| Follow-up chemotherapy |
|
|
| None |
13 |
50 |
| Concurrent |
3 |
11 |
| Adjuvant |
15 |
50 |
| Regimen |
|
|
| S-1 |
5 |
18 |
| GEM |
7 |
25 |
| S-1 + GEM |
2 |
7 |
| GEM + CDDP | 1 | 4 |
BED, biologically effective dose; S-1, tegafur, gimeracil, and oteracil; CDDP, cisplatin; RBE, relative biological effectiveness.